Cerity Partners LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 30.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 199,425 shares of the company's stock after buying an additional 46,575 shares during the quarter. Cerity Partners LLC's holdings in AstraZeneca were worth $15,537,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in the business. CANADA LIFE ASSURANCE Co boosted its position in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after acquiring an additional 146 shares in the last quarter. Toronto Dominion Bank raised its position in AstraZeneca by 15.2% during the first quarter. Toronto Dominion Bank now owns 18,493 shares of the company's stock valued at $1,253,000 after purchasing an additional 2,447 shares in the last quarter. Silvercrest Asset Management Group LLC raised its position in AstraZeneca by 65.5% during the first quarter. Silvercrest Asset Management Group LLC now owns 39,915 shares of the company's stock valued at $2,704,000 after purchasing an additional 15,794 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in AstraZeneca during the first quarter valued at approximately $914,000. Finally, B. Riley Wealth Advisors Inc. raised its position in AstraZeneca by 36.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 23,504 shares of the company's stock valued at $1,592,000 after purchasing an additional 6,224 shares in the last quarter. Institutional investors own 20.35% of the company's stock.
Analyst Ratings Changes
AZN has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Finally, TD Cowen boosted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $89.75.
Read Our Latest Stock Report on AZN
AstraZeneca Trading Down 0.3 %
Shares of AstraZeneca stock traded down $0.19 during trading on Tuesday, hitting $66.21. The company's stock had a trading volume of 2,558,623 shares, compared to its average volume of 5,319,567. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a market cap of $205.29 billion, a price-to-earnings ratio of 31.77, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. The stock has a 50-day moving average price of $73.19 and a two-hundred day moving average price of $77.72.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analysts' expectations of $13.08 billion. During the same quarter in the previous year, the firm posted $0.87 earnings per share. AstraZeneca's revenue for the quarter was up 18.0% on a year-over-year basis. Equities research analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.